Analysed IMMUNITYBIO INC (IBRX:NASDAQ) News Sources
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses
07-08-2026
yahoo.com
SLS And IBRX Eye Green Weekly Close: Vanguard’s Major Stakes In Cancer Drugmakers Steal The Spotlight
14-08-2026
stocktwits.com
Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom
17-08-2026
stocktwits.com
SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
26-08-2026
stocktwits.com
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
27-08-2026
stocktwits.com
IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update
27-08-2026
stocktwits.com
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
01-09-2026
stocktwits.com
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
10-09-2026
stocktwits.com
What is the current price of IMMUNITYBIO INC (IBRX:NASDAQ)?
The current price of IMMUNITYBIO INC (IBRX:NASDAQ) is $8.16.
IMMUNITYBIO INC (IBRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMUNITYBIO INC (IBRX:NASDAQ) since the previous trading day is $0.44.
IMMUNITYBIO INC (IBRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMUNITYBIO INC (IBRX:NASDAQ) since the previous trading day is 5.6995%.
What is the most recent average sentiment score for IMMUNITYBIO INC (IBRX:NASDAQ)?
The most recent average sentiment score for IMMUNITYBIO INC (IBRX:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for IMMUNITYBIO INC (IBRX:NASDAQ)?
The most recent sentiment for IMMUNITYBIO INC (IBRX:NASDAQ) is .
SEC-8K** Filing Available For IMMUNITYBIO INC (IBRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.